Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?
Key PointsPfizer has made significant progress in addressing some of its challenges.
Pfizer (NYSE: PFE) has faced a tumultuous period in recent years, grappling with macroeconomic challenges, a significant decline in sales from its coronavirus portfolio, and looming patent expirations, particularly for its flagship anticoagulant drug, Eliquis. However, Pfizer's CEO, Albert Bourla, recently conveyed at a conference that the company's headwinds are beginning to ease. Here's a closer look at the situation.
Bourla highlighted three primary headwinds Pfizer encountered in 2025: tariffs and drug pricing policies, dwindling sales of its coronavirus products, and patent cliffs. He claimed that the company had successfully addressed the first issue by reaching agreements with the U.S. government, which granted Pfizer tariff breaks in return for selling selected medicines at discounted prices domestically.
While Pfizer's COVID-related sales are still subpar this year, Bourla pointed out that the pharmaceutical giant has, overall, outperformed Wall Street's earnings-per-share (EPS) estimates in recent quarters. In fact, Bourla highlighted that over the past ten consecutive quarterly reporting periods, Pfizer has consistently exceeded EPS expectations, and has managed to exceed revenue forecasts in nine out of ten instances.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
